Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.48 Analyst target: $25.71 Upside: 936.69%
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.